[Double-blind versus placebo comparison of single dose alpidem (50 mg or 75 mg) in a model of situational anxiety]

Abstract

Alpidem (Ananxyl) is a new imidazopyridine anxiolytic. Two studies of single doses of alpidem (50 or 75 mg) versus placebo, involving 104 patients each, showed alpidem at these two doses to be effective in a human model for situational anxiety, which is the psychological state of patients awaiting cardiovascular examination or surgery. Clinical assessment showed no significant difference in safety between alpidem 50 mg and placebo. Conversely, at the dose of 75 mg, there was a higher incidence of drowsiness with alpidem than with placebo.